Polypoidal Choroidal Vasculopathy Clinical Trials

42 clinical trials for Polypoidal Choroidal Vasculopathy across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy — RECRUITING · PHASE3
• Study to Investigate the Efficacy, Safety and Durability of Faricimab in Caucasian Patients With Polypoidal Choroidal Vasculopathy (MONDEGO) — RECRUITING · PHASE4
• Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial — RECRUITING · PHASE3
• OCT in Rare Chorioretinal Diseases — RECRUITING
• A randomized, double-masked, sham-controlled phase 3b/4 study of the efficacy, safety, and tolerability of intravitreal aflibercept monotherapy compared to aflibercept with adjunctive photodynamic therapy as indicated in subjects with polypoidal choroidal vasculopathy (PLANET) — COMPLETED · PHASE4
• A phase IV, multicentre, open-label, single-arm study to investigate the efficacy, safety and durability of faricimab (RO6867461) in caucasian patients with polypoidal choroidal vasculopathy — TERMINATED · PHASE4
• A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV) — NOT_YET_RECRUITING · PHASE4
• Comparing Intravitreal Aflibercept Monotherapy vs Aflibercept Combined With Reduced Fluence PDT in PCV Treatment — COMPLETED · NA
• Long-term Outcomes, Recurrence Rates, and Treatment Needs in Polypoidal Choroidal Vasculopathy (PCV) — COMPLETED
• Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV — COMPLETED
• Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy — COMPLETED · PHASE1
• Clinical Implication of Aflibercept in PCV Treatment in China — OTHER
• Conbercept for Polypoidal Choroidal Vasculopathy（START Study） — COMPLETED
• An Open Label-study to Compare the Efficacy of Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy — COMPLETED · PHASE4
• OCTA and Polypoidal Choroidal Vasculopathy — COMPLETED
• Interval of Disease Inactivity After Complete Polypoidal Regression in PCV Receiving Aflibercept — OTHER · NA
• Efficacy and Safety of Two Regimens of Anti-VEGF Therapy in Chinese Patients With Polypoidal Choroidal Vasculopathy — OTHER · PHASE4
• Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal Vasculopathy — COMPLETED · PHASE4
• Intraocular Cytokine in Recurrence of Polypoidal Choroidal Vasculopathy — OTHER · PHASE4
• Biomarkers of Common Eye Diseases — OTHER
• Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy — TERMINATED · PHASE2
• Initial Versus Delayed PDT Combination With Conbercept in PCV — COMPLETED · PHASE4
• Visual Outcome in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy (PCV) Treated With Either Ranibizumab as Monotherapy or Combined With Verteporfin Photodynamic Therapy (vPDT) — COMPLETED · PHASE4
• Ranibizumab (Lucentis) for Polypoidal Choroidal Vasculopathy — COMPLETED · PHASE1
• Comparison of PDT, Intravitreal Ranibizumab and Combination for Polypoidal Choroidal Vasculopathy Under 1+PRN Regimen — COMPLETED · NA
• Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept Treatment — COMPLETED · NA
• Investigator Sponsored Trial of Polypoidal Choroidal Vasculopathy (PCV) Evaluation Assessing High-Dose Ranibizumab Prospectively (PEARL2) — COMPLETED · PHASE1
• The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV) — OTHER · PHASE4
• Pharmacogenomic Study on Anti-VEGF Medicine in Treatment of Macular Neovascular Diseases — OTHER
• Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or Exudation — COMPLETED · PHASE4
• Short-term Efficacy of Intravitreal Afilibercept Depending on Subtypes of Polypoidal Choroidal Vasculopathy: Polypoidal Choroidal Neovascularization or Idiopathic Choroidal Vasculopathy — OTHER
• Angiographic Characteristics of CSC, PCV Patients and Thrombotic Bio-markers — OTHER
• Effect of Intravitreal VEGF-Trap Eye on Polypoidal Choroidal Vasculopathy — COMPLETED · PHASE4
• Ranibizumab for Polypoidal Choroidal Vasculopathy (PCV) — COMPLETED · PHASE1
• Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy — COMPLETED · PHASE1
• Study Evaluating the Safety and Response of Fosbretabulin in Asian Patients With Polypoidal Choroidal Vasculopathy (PCV) — COMPLETED · PHASE2
• Aqueous Humor Level of Cytokines in Polypoidal Choroidal Vasculopathy and Change of Cytokines After Photodynamic Therapy — OTHER · NA
• Efficacy and Safety of Verteporfin Added to Ranibizumab in the Treatment of Symptomatic Macular Polypoidal Choroidal Vasculopathy — COMPLETED · PHASE4
• Response to Ranibizumab in Polypoidal Choroidal Vasculopathy (PCV)and SNPs — COMPLETED
• Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy — OTHER · PHASE1
• Off-Label AVASTIN (BEVACIZUMAB) For Serosanguinous Maculopathy — OTHER · PHASE3
• Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy — OTHER · NA

Refine this search